Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage Therapy with Abacavir, Amprenavir, Lamivudine and PI Switch in HIV
NCT00002423Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abacavir and amprenavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by GSK. Primary endpoints: Safety at 48 weeks and Effectiveness at 48 weeks. Started Mar 1999; status: completed.
02
Drugs
abacaviramprenavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002423.